Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 740-744

  Lin, Lijuan ^a   Zhang, Jinhui ^a   Wang, Yan ^a   Ju, Weiei ^a   Ma, Yibing ^b   Li, Lina ^c   Chen, Litian ^d  

^a EASTERN LIAONING UNIVERSITY   (China)

^b First Hospital of Dandong City   (China)

^c Department of Ophthalmology Tianjin First Centre Hospital   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal adenocarcinoma; Immunohistochemistry; Insulin like growth factor II mRNA binding protein 3; Prognosis

Indexed keywords

KI 67 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPLASIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 84880408272     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1458     Document Type: Article

References (23)

1. Lim SC and Hong R: Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage. Oncol Lett 2: 1053-1057, 2011.
2. Alwan A: World Health Organization. Disaster Med Public Health Prep 1: 7-8, 2007.
3. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, et al: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 10: 341, 2010.
4. Mentrikoski MJ, Ma L, Pryor JG, et al: Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol 22: 1582-1587, 2009.
5. Hoffmann NE, Sheinin Y, Lohse CM, et al: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112: 1471-1479, 2008.
6. Jiang Z, Chu PG, Woda BA, et al: Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 14: 5579-5584, 2008.
7. Schaeffer DF, Owen DR, Lim HJ, et al: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10: 59, 2010.
8. Mhawech-Fauceglia P, Herrmann FR, Rai H, et al: IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol 133: 899-908, 2010.
9. Lu D, Yang X, Jiang NY, et al: IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 35: 1638-1645, 2011.
10. Hammer NA, Hansen TV, Byskov AG, et al: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 130: 203-212, 2005.
11. Li C, Rock KL, Woda BA, et al: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 20: 242-247, 2007.
12. Gress TM, Müller-Pillasch F, Geng M, et al: A pancreatic cancer-specific expression profile. Oncogene 13: 1819-1830,1996.
13. Nielsen J, Christiansen J, Lykke-Andersen J, et al: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19: 1262-1270, 1999.
14. Tosun Yildirim H and Sentürk N: Analysis of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg 28: 128-133, 2012.
15. Liao B, Hu Y, Herrick DJ and Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280: 18517-18524, 2005.
16. Jeng YM, Wang TH, Lu SH, et al: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg 96: 66-73, 2009.
17. Xu C, Jiang XZ, Zhao HF, et al: The applicability of Ki-67 marker for renal epithelioid angiomyolipoma: experience of ten cases from a single center. Neoplasma 60: 209-214, 2013.
18. Wang L, Li HG, Xia ZS, et al: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl) 123: 3554-3558, 2010.
19. Sitnikova L, Mendese G, Liu Q, et al: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14: 1701-1706, 2008.
20. Yaniv K, Fainsod A, Kalcheim C and Yisraeli JK: The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development 130: 5649-5661, 2003.
21. Yantiss RK, Cosar E and Fischer AH: Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol 52: 133-138, 2008.
22. Okada K, Fujiwara Y, Nakamura Y, et al: Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol 105: 780-785, 2012.
23. Wachter DL, Kristiansen G, Soll C, et al: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology 60: 278-286, 2012.